My account
Injectables Orals Peptides Human Growth Hormone SARMs
Sign in
A
Anastrozole
B
Bacteriostatic water Boldenone undecylenate
C
Clenbuterol Clomiphene citrate Cabergoline
D
Drostanolone enanthate Drostanolone propionate Dehydroepiandrosterone (DHEA)
E
Erythropoietin Exemestane
F
Fluoxymesterone
H
Human chorionic gonadotropin Human growth hormone (HGH)
L
Liothyronine sodium
M
Mecasermin Meldonium Mesterolone Methandienone Methenolone acetate Methenolone enanthate Melanotan-2
N
Nandrolone decanoate Nandrolone phenylpropionate
O
Oxandrolone Oxymetholone
S
Sildenafil citrate Stanozolol
T
Trenbolone enanthate Trestolone acetate Trenbolone acetate Testosterone undecanoate Testosterone propionate Testosterone base and suspension Tadalafil citrate Testosterone cypionate Testosterone enanthate Tamoxifen citrate Turinabol
Y
Yohimbine
Show 164 results
Manufacturers
Categories
Substances
Disagree
Home Beligas Pharmaceuticals Beligas Pharmaceuticals
SARMS-STENABOLIC
SARMS-STENABOLIC - Beligas Pharmaceuticals

SARMS-STENABOLIC - Beligas Pharmaceuticals

Brand:
Beligas Pharmaceuticals
Category:
SARMs
Substance:
Stenabolic
Dosage:
20 mg/tab
Package:
50 tablets
Price:
0
See options
Product Overview
SR9009, developed to act on circadian rhythm pathways, has demonstrated unexpected efficacy in combating prostate cancer. Unlike conventional androgen-targeting treatments, it disrupts the LXRα/FOXM1 axis, a critical signaling pathway in aggressive PCS1 tumors. Research shows that SR9009 significantly impairs cancer cell viability, reduces migration, and induces apoptosis while leaving healthy prostate cells largely unaffected. This targeted approach positions SR9009 as a potential non-hormonal therapeutic strategy for advanced prostate cancer management .
References:

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about SARMS-STENABOLIC by Beligas Pharmaceuticals, consult with your doctor or healthcare professional.

Explore More Products
Reviews
Leave Review
FAQ
What is Stenabolic used for in cancer research?
Stenabolic (SR9009) is being studied for treating aggressive prostate cancer, especially the PCS1 subtype.
References:

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.

Does Stenabolic work like hormone-based treatments?
No, Stenabolic does not target androgen receptors and works through a different mechanism.
References:

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.

Is Stenabolic toxic to healthy tissue?
No, it targets cancer cells without damaging normal cells in studies.
References:

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.